Searched for
CIPLA CEO
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- Nifty in control of FIIs? The unlucky 13 bluechips facing the hardest institutional selloffForeign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Is India Inc's CSR truly driving systemic change or just shifting funds?Corporate India is entering a new phase of CSR. Spending is expected to cross ₹1.2 lakh crore by 2035. Companies are shifting towards syste...
- Cipla Q4 net profit slumps 55% YoY to Rs 555 crore, full-year PAT down 26%Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the f...
- Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividendCipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Cohance Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surgeCohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Cipla global CEO Umang Vohra to step down; Achin Gupta to take overCipla's global CEO Umang Vohra will step down in March 2026. Achin Gupta, currently global COO, will take over as the new MD and GCEO from ...
- 65% of CEOs keen to switch fields: SurveyThe reasons for this huge increase could be varied, but this is a trend that they approve of.
- Need more women on boards? Hire a female CEO“Women CEOs show an enlightened attitude to boards and promoters. A greater gender diversity at board level is a desirable outcome for comp...
- Cipla bags Rs 1,100 crore order from South African governmentCipla Medpro, the SA subsidiary of the Indian firm, has bagged the order as part of the South African government's 2015-17 National ARV ten...
- Cipla, BioQuiddity ink pact to sell pain management productCipla intends to launch the CE marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this y...
- Cipla completes the Medpro deal, buys 100% stake in the South African companyThe total consideration payable by Cipla is approximately $ 512 million or ZAR 4.5 billion.
Load More
